RecruitingPhase 2NCT06275919

Regorafenib for Recurrent Meningioma (MIRAGE Trial)

Studying Meningioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Istituto Oncologico Veneto IRCCS
Principal Investigator
Giuseppe Lombardi, MD, MD, PHD
Istituto Oncologico Veneto IOV IRCCS
Intervention
Regorafenib 40 MG Oral Tablet(drug)
Enrollment
104 enrolled
Eligibility
18 years · All sexes
Timeline
20242027

Study locations (17)

Collaborators

Bayer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06275919 on ClinicalTrials.gov

Other trials for Meningioma

Additional recruiting or active studies for the same condition.

See all trials for Meningioma

← Back to all trials